Final Results From the ATALANTE/ENGOT-ov29 Randomized Phase III Trial of Atezolizumab, Bevacizumab, and Platinum-Based Therapy for Late-Relapsing Recurrent Ovarian Cancer
Jean‐Emmanuel Kurtz, Éric Pujade-Lauraine, Ana Oaknin, Lisa Belin et autres
PURPOSE Previously reported results from the placebo-controlled double-blind randomized phase III ATALANTE/ENGOT-ov29 trial (ClinicalTrials.gov identifier: NCT02891824 ) showed that progression-free survival improvement with the addition of atezolizumab to standard bevacizumab and platinum-based chemotherapy for late-relapsing recurrent ovarian cancer did not reach statistical …
fr, es, at, cz, be, il, de (code pays fourni par la source)
0 citations
JCO oncology advances.